Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.37 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 3/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | CLK1 | P49759 | 2/20 | 0.33 |
| ▸ | PLK4 | O00444 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | PRKACA | P17612 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089827 | 0.79 | IP6K1 (0.38) | EGFRDHFRCDC7IP6K1DYRK1A | |
| SCHEMBL5089833 | 0.79 | IP6K1 (0.38) | EGFRDHFRCDC7IP6K1DYRK1A | |
| SCHEMBL5095473 | 0.79 | IP6K1 (0.38) | EGFRDHFRCDC7IP6K1DYRK1A | |
| SCHEMBL5094652 | 0.65 | POLB (0.42) | EGFRCDC7 | |
| SCHEMBL5101093 | 0.65 | POLB (0.42) | EGFRCDC7 | |
| SCHEMBL5089603 | 0.65 | SMN1; SMN2 (0.44) | EGFRCDC7IP6K1RET | |
| SCHEMBL5094643 | 0.65 | POLB (0.42) | EGFRCDC7 | |
| SCHEMBL5092683 | 0.65 | SMN1; SMN2 (0.44) | EGFRCDC7IP6K1RET | |
| SCHEMBL5089591 | 0.65 | SMN1; SMN2 (0.44) | EGFRCDC7IP6K1RET | |
| SCHEMBL13821349 | 0.63 | ALDH1A1 (0.48) | GSK3BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | disclosed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K6, MAP3K1 | EGFR 678/4885DHFR 756/4885CDC7 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.